New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:25 EDTRHT, NKE, CEMI, HALO, PFE, RIMM, WAG, TSPTOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Red Hat (RHT), up 5.4%... Nike (NKE), up 3%... ALSO HIGHER: Chembio Diagnostics (CEMI), up 20.7% after receiving FDA approval for its rapid HIV test... Halozyme (HALO), up 17.4% after entering a development collaboration with Pfizer (PFE)... Ameristar Casinos (ASCA), up 17% after agreeing to be acquired by Pinnacle Entertainment (PNK) for $26.50 per share... LOWER AFTER EARNINGS: Research in Motion (RIMM), down 16.3%... Walgreen (WAG), down 1.7%... ALSO LOWER: Transcept (TSPT), down 14.7% after Phase 2 trial of OCD drug misses primary endpoint.
News For RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
09:03 EDTWAGWalgreen venture investment head leaves after short time in post, Fortune says
Bill Wafford, who was named managing director of Walgreen’s venture capital and growth equity investment business Well Ventures just this this past January, has left the company, according to Fortune. Reference Link
08:14 EDTWAGWalgreen sued by former CFO for defamation, Reuters reports
Wade Miquelon, the former CFO of Walgreen, filed a lawsuit yesterday in state court in Chicago alleging that CEO Gregory Wasson and director Stefano Pessina, the company's biggest shareholder defamed him in news reports that blamed him for errors in its earnings forecast, Reuters reports. The Wall Street Journal reported in August that Miquelon lost his job following a $1B error in forecasting Walgreen's Medicare-related business, and later said Miquelon's error caused the company to cut its forecast in pharmacy unit earnings for the year ending August 2016. Reference Link
October 16, 2014
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:01 EDTRHTRed Hat, Cloudera announce alliance to deliver enterprise software solutions
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
10:02 EDTNKEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:28 EDTNKENike upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
06:12 EDTNKENike's Converse sues rivals over 'copycat' design, NY Post reports
Converse, a unit of Nike (NKE), is suing rivals including Ralph Lauren (RL) and Tory Burch, alleging that shoemakers and retailers are copying its iconic design, the New York Post reports. Lawyers for Converse say "We welcome fair competition, but we do not believe companies have a right to copy the trademarked look." The lawsuit seeks unspecified damages and injunctions that would bar the production of the rival shoe models. Reference Link
October 14, 2014
17:16 EDTTSPTTranscept Pharmaceuticals declares special dividend of $12.79M, or 66c per share
Subscribe for More Information
11:23 EDTPFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
06:03 EDTWAGWalgreen implied volatility of 27 at lower end of index mean range
Subscribe for More Information
October 13, 2014
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
06:41 EDTWAGWalgreens to roll out Apple Pay on October 18, MacRumors reports
Walgreens (WAG) will begin rolling out Apple Pay (AAPL) on Saturday, October 18, according to a memo obtained by MacRumors. Reference Link
06:13 EDTWAGWalgreen implied volatility of 25 at lower end of index mean range
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use